ImmunityBio, Inc. (IBRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, ImmunityBio, Inc. reported revenue of $113.29M, up 668.3% from the prior year. The company ran a net loss, with a net margin of -310.2%. It held $501.90M in total assets against $1.00B in total liabilities.
Key ratios (FY2025)
-226.0%
Operating margin
-310.2%
Net margin
+668.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.29M | $14.74M | $622.0K | $240.0K | $934.0K | $605.0K | $2.20M | $47.0K | $45.0K | $44.0K |
| Cost of Revenue | $753.0K | $0 | $0 | $0 | — | — | — | — | — | — |
| Operating Income | -$256.03M | -$344.18M | -$362.25M | -$351.30M | -$330.28M | -$220.88M | -$156.25M | -$98.39M | -$99.12M | -$124.50M |
| Net Income | -$351.40M | -$413.56M | -$583.20M | -$416.57M | -$346.79M | -$221.85M | -$157.78M | -$96.23M | -$96.42M | -$120.81M |
| EPS (Diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | — | — | — |
| Total Assets | $501.90M | $382.93M | $504.45M | $362.36M | $468.91M | $221.38M | $143.12M | $181.95M | $250.44M | $317.50M |
| Total Liabilities | $1.00B | $871.06M | $1.09B | $812.18M | $712.82M | $339.87M | $22.44M | $35.94M | $31.60M | $24.08M |
| Shareholders' Equity | -$500.47M | -$489.10M | -$586.99M | -$447.33M | -$242.17M | -$119.81M | $120.68M | $146.01M | $218.84M | $293.42M |
| Cash & Equivalents | $88.33M | $143.43M | $265.45M | $104.64M | $181.10M | $34.91M | $75.80M | $16.82M | $23.87M | $8.08M |
| Operating Cash Flow | -$304.94M | -$391.24M | -$366.76M | -$337.51M | -$274.42M | -$171.72M | -$152.11M | -$63.38M | -$48.78M | -$38.59M |
| Capital Expenditures | $3.85M | $6.89M | $30.58M | $78.16M | $33.56M | $1.67M | $4.29M | $13.10M | $34.81M | $6.56M |
| Shares Outstanding | 1.01B | 852.90M | 670.87M | 421.57M | 397.83M | 382.24M | 98.46M | 79.09M | 79.02M | 81.98M |